Visterra-Serum Combine Forces For Dengue Therapy

US biotech, Visterra, has joined hands with vaccine giant, Serum Institute of India, to take its early stage monoclonal antibody product candidate (VIS513) for dengue forward.

US biotech, Visterra, has joined hands with vaccine giant, Serum Institute of India, to take its early stage monoclonal antibody product candidate (VIS513) for dengue forward.

Earlier this year, Visterra formed a collaboration with Singapore's Agency for Science, Technology and Research (A*STAR) for VIS513 and the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anti-infective

More from Therapeutic Category